From our Expert Voices conversation on drug pricing.

Innovative drugs like Kymirah deserve innovative reimbursement contracts – paying for value, not by the pill. Novartis is embracing that adage, and offering to waive the drug's $475,000 fee for patients who don't respond.

That's great, but we're not just paying for medicines. Bundled payments for all oncology-associated care (including hospital, ER costs, and physician visits) linked to patient outcomes can encourage providers and drug companies to collaborate — and compete— on delivering the best outcome for each patient as efficiently as possible.

Kymirah can make a great test case for this approach. Treatment centers that specialize in gene and cellular therapies can work with Novartis and other companies to build detailed patient registries that help oncologists use "real-world data" on what really happens to patients — and why — to improve outcomes while reducing unnecessary costs and avoidable side effects. We already take a similar approach with patient registries and bundled payments for organ transplants.

The bottom line: An outcomes-based payment system can help us put more patients' cancers into remission for longer periods of time – with fewer wasted treatments, and less need for follow on therapies. That's greater value for every dollar we spend on cancer care.

Other voices in the conversation:

  • Greg Aune, pediatric oncologist, Greehey Children's Cancer Research Institute: Value isn't just about surviving cancer
  • David Mitchell, president and founder, Patients for Affordable Drugs: Drugs don't work if people can't afford them
  • Usman Azam, president & CEO, Tmunity Therapeutics: How to evaluate breakthrough therapies
  • Austin Frakt, health economist, Department of Veterans Affairs, Boston University and Harvard University: The public should have a say in what a drug is worth

Go deeper

The apocalypse scenario

Illustration: Aïda Amer/Axios

Democratic lawyers are preparing to challenge any effort by President Trump to swap electors chosen by voters with electors selected by Republican-controlled legislatures. One state of particular concern: Pennsylvania, where the GOP controls the state house.

Why it matters: Trump's refusal to commit to a peaceful transfer of power, together with a widely circulated article in The Atlantic about how bad the worst-case scenarios could get, is drawing new attention to the brutal fights that could jeopardize a final outcome.

Federal judge rules Trump administration can't end census early

Census workers outside Lincoln Center in New York. Photo: Noam Galai/Getty Images

A federal judge ruled late Thursday that the Trump administration could not end the 2020 census a month early.

Why it matters: The decision states that an early end — on Sept. 30, instead of Oct. 31 — would likely produce inaccuracies and thus impact political representation and government funding around the country.

Caitlin Owens, author of Vitals
2 hours ago - Health

Where bringing students back to school is most risky

Data: Coders Against COVID; Note: Rhode Island and Puerto Rico did not meet minimum testing thresholds for analysis. Values may not add to 100% due to rounding; Cartogram: Andrew Witherspoon/Axios

Schools in Southern and Midwestern states are most at risk of coronavirus transmission, according to an analysis by Coders Against COVID that uses risk indicators developed by the Centers for Disease Control and Prevention.

The big picture: Thankfully, schools have not yet become coronavirus hotspots, the Washington Post reported this week, and rates of infection are lower than in the surrounding communities. But that doesn't mean schools are in the clear, especially heading into winter.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Subscription failed
Thank you for subscribing!